Physician profile
Ligi Abraham
NPI 1376158295
$2,773.53
in general payments reported to CMS, 2019-2025
24 companies · $1,130 in 2025
The $1,130 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,161 · 2022: $21.21 · 2023: $54.46 · 2024: $407 · 2025: $1,130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,591.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,590.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $809.95 | 2021-2025 | Andexxa |
| Incyte Corporation | $218.95 | 2025 | Zynyz, Zynyz |
| Caris Mpi, INC. | $210.07 | 2025 | Mi Cancer Seek |
| Novartis Pharmaceuticals Corporation | $169.67 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $166.91 | 2024-2025 | Keytruda |
| Histosonics, INC. | $135.05 | 2025 | |
| Astellas Pharma US INC | $122.19 | 2024 | Vyloy |
| Pharming Healthcare, INC. | $117.66 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $114.91 | 2021-2025 | Fruzaqla |
| Csl Behring | $110.40 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $93.68 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $76.86 | 2021 | |
| Kaleo, INC. | $71.89 | 2021 | |
| Grifols USA, LLC | $69.64 | 2021 | |
| Exelixis INC. | $65.47 | 2025 | Cabometyx |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $48.29 | 2024 | Opdivo |
| Array Biopharma INC | $44.52 | 2024-2025 | Mektovi, Braftovi, Tukysa |
| Recordati_rare_diseases_inc. | $24.46 | 2023 | Sylvant |
| Astellas Pharma Global Development | $22.99 | 2024 | Vyloy |
| Alk-Abello, INC | $17.32 | 2021 | |
| Deciphera Pharmaceuticals INC. | $17.11 | 2025 | Romvimza, Qinlock |
| Solventum Corporation | $16.79 | 2025 | V.A.C. Dermatac, V.A.C. Veraflo Cleanse Choice, V.A.C.Ulta |
| Adma Biomanufacturing LLC | $15.31 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $13.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ligi Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.